 | Up a level |
Schnegg-Kaufmann, A; Calzavarini, S; Limacher, A; Mean, M; Righini, M; Staub, D; Beer, J H; Frauchiger, B; Osterwalder, J; Kucher, N; Matter, C M; Husmann, M; Banyai, M; Aschwanden, M; Mazzolai, L; Hugli, O; Nagler, M; Daskalakis, M; Rodondi, N; Aujesky, D; ... (2019). High gas6 in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly. Journal of thrombosis and haemostasis, 17(2), pp. 306-318. Wiley-Blackwell 10.1111/jth.14365
Asmis, L M; Alberio, L; Angelillo-Scherrer, A; Korte, W; Mendez, A; Reber, G; Seifert, B; Stricker, H; Tsakiris, D A; Wuillemin, W A (2011). Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories. Thrombosis research, 129(4), pp. 492-498. Amsterdam: Elsevier 10.1016/j.thromres.2011.06.031
Keller, P; Angelillo-Scherrer, A; Bargetzi, M; Goede, J; Hess, U; Imbach, P; Mach-Pascual, S; Mey U Rüfer, A; Schmidt, A (2010). Diagnose und Behandlung der primären Immun-Thrombozytopenie. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS, 10(50), pp. 875-883. Basel: EMH Editores Medicorum Helveticorum
